[go: up one dir, main page]

AR087755A1 - Derivados de heterociclos biciclicos para el tratamiento de la hipertension arterial pulmonar - Google Patents

Derivados de heterociclos biciclicos para el tratamiento de la hipertension arterial pulmonar

Info

Publication number
AR087755A1
AR087755A1 ARP120103226A ARP120103226A AR087755A1 AR 087755 A1 AR087755 A1 AR 087755A1 AR P120103226 A ARP120103226 A AR P120103226A AR P120103226 A ARP120103226 A AR P120103226A AR 087755 A1 AR087755 A1 AR 087755A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
alkoxy
heterocyclyl
halogen
Prior art date
Application number
ARP120103226A
Other languages
English (en)
Inventor
Bruce Ian
Chamoin Sylvie
Paul Collingwood Stephen
Lewis Sarah
Christopher Loren Jon
Molteni Valentina
Michael Saunders Alex
Shaw Duncan
Sviridenko Lilya
Thompson Christopher
Yeh Vince
Janus Diana
West Ryan
Furminger Vikki
Furet Pascal
Original Assignee
Novartis Ag
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47018333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR087755(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Irm Llc filed Critical Novartis Ag
Publication of AR087755A1 publication Critical patent/AR087755A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Útiles en la inhibición de la actividad biológica mediada por el receptor PDGF. Reivindicación 1: Un compuesto representado por la fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde, A es un compuesto de formula (2) ó (3); R¹ es alquilo C₁₋₄; alcoxilo C₁₋₄ opcionalmente sustituido por uno o más átomos de halógeno; CN; ó halógeno; R¹ᵃ es H, halógeno, alquilo C₁₋₄ ó haloalquilo C₁₋₄; X es N ó CH; R² es H; alquilo C₁₋₈ opcionalmente sustituido por uno o más OH, -NR⁹R¹¹ ó alcoxilo C₁₋₄; haloalquilo C₁₋₈; alquinilo C₂₋₈ sustituido por uno o más halógeno, OH, -NR⁹R¹¹ ó alcoxilo C₁₋₄; cicloalquilo C₃₋₁₀; -(alquilo C₁₋₄)-cicloalquilo C₃₋₈; alcoxilo C₁₋₈ opcionalmente sustituido por uno o más halógeno, -NR⁹R¹¹ u OH; OH; CN; halógeno; -(alquilo C₀₋₄)-NR⁹R¹¹; -(alquilo C₀₋₄)-CO₂R¹⁵; -(alquilo C₀₋₄)-C(O)NR⁹R¹¹; -(alquilo C₀₋₄)-arilo C₆₋₁₄; ó -(alquilo C₀₋₄)-heterociclilo de 3 a 14 miembros; en donde el cicloalquilo, -(alquilo C₀₋₄)-arilo C₆₋₁₄ y -(alquilo C₀₋₄)-heterociclilo de 3 a 14 miembros son cada uno opcionalmente sustituidos por uno o más sustituyentes de Zᵃ; R³ es H; alquilo C₁₋₈ opcionalmente sustituido por uno o más OH, -NR⁹R¹¹ ó alcoxilo C₁₋₄; haloalquilo C₁₋₈; alquinilo C₂₋₈ sustituido por uno o más halógeno, OH, -NR⁹R¹¹, ó alcoxilo C₁₋₄; cicloalquilo C₃₋₁₀; -(alquilo C₁₋₄)-cicloalquilo C₃₋₈; alcoxilo C₁₋₈ opcionalmente sustituido por uno o más halógeno, -NR⁹R¹¹ u OH; OH; CN; halógeno; -(alquilo C₀₋₄)-NR⁹R¹¹; -(alquilo C₀₋₄)-CO₂R¹⁵; -(alquilo C₀₋₄)-C(O)NR⁹R¹¹; -(alquilo C₀₋₄)-arilo C₆₋₁₄; ó -(alquilo C₀₋₄)-heterociclilo de 3 a 14 miembros; en donde el cicloalquilo, -(alquilo C₀₋₄)-arilo C₆₋₁₄ y -(alquilo C₀₋₄)-heterociclilo de 3 a 14 miembros son cada uno opcionalmente sustituidos por uno o más sustituyentes de Zᵃ; cada Zᵃ es independientemente OH; (alquilo C₀₋₄)-arilo C₆; O-arilo C₆; alquilo C₁₋₄ opcionalmente sustituido por uno o más OH, CN ó -NR¹⁹ᵃR²¹ᵃ; haloalquilo C₁₋₄; alcoxilo C₁₋₄ opcionalmente sustituido por uno o más OH, -CO₂R¹⁹ᵃ, -NR¹⁹ᵃR²¹ᵃ ó alcoxilo C₁₋₄; -NR¹⁸ᵃC(O)R²¹ᵃ; -C(O)NR¹⁹ᵃR²¹ᵃ; -NR¹⁸ᵃC(O)NR¹⁹ᵃR²¹ᵃ; -NR¹⁹ᵃR²¹ᵃ; -(alquilo C₀₋₄)-C(O)OR¹⁸ᵃ; -(alquilo C₀₋₄)-C(O)R¹⁹ᵃ; oxo; CN; NO₂; halógeno; -(alquilo C₀₋₄)-heterociclilo de 4 a 6 miembros; ó -O-(heterociclilo de 4 a 6 miembros); en donde el (alquilo C₀₋₄)-arilo C₆, O-arilo C₆, -(alquilo C₀₋₄)-heterociclilo de 4 a 6 miembros y -O-(heterociclilo de 4 a 6 miembros) son cada uno opcionalmente sustituidos por OH, halógeno, alquilo C₁₋₄, haloalquilo C₁₋₄ ó alcoxilo C₁₋₄ opcionalmente sustituido por uno o más halógenos; R⁴ es H; R⁵ es H, alquilo C₁₋₄ o haloalquilo C₁₋₄; R⁶ se selecciona a partir de alquilo C₁₋₈ opcionalmente sustituido por uno o más alcoxilo C₁₋₄ ó -NR¹⁹R²¹; haloalquilo C₁₋₈; -(alquilo C₀₋₄)-cicloalquilo C₃₋₈; alcoxilo C₁₋₈ opcionalmente sustituido por uno ó más átomos de halógeno; -NR¹⁹R²¹; -(alquilo C₀₋₄)-arilo C₆₋₁₄; y -(alquilo C₀₋₄)-heterociclilo de 3 a 14 miembros; en donde el -(C₀₋₄alquilo)-cicloalquilo C₃₋₈, -(alquilo C₀₋₄)-arilo C₆₋₁₄ y -(alquilo C₀₋₄)-heterociclilo de 3 a 14 miembros son cada uno opcionalmente sustituidos por uno o más sustituyentes de Z; cada Z se selecciona independientemente a partir de (alquilo C₀₋₄)-arilo C₆; O-arilo C₆; alquilo C₁₋₆ opcionalmente sustituido por uno o más alcoxilo C₁₋₆, CN ó -NR¹⁹R²¹; haloalquilo C₁₋₆; alcoxilo C₁₋₆ opcionalmente sustituido por uno o más -NR¹⁹R²¹ ó alcoxilo C₁₋₄; -NR¹⁹R²¹; (alquilo C₀₋₄)-C(O)R¹⁹; CN; halógeno y (alquilo C₀₋₄)-heterociclilo de 4 a 6 miembros; y en donde el arilo y heterociclilo son cada uno opcionalmente sustituidos por uno o más halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆ y alcoxilo C₁₋₆ opcionalmente sustituido por uno o más halógenos; R⁹ y R¹¹ son cada uno independientemente seleccionados a partir de H; alquilo C₁₋₆ opcionalmente sustituido por uno o más alcoxilo C₁₋₄ u OH; haloalquilo C₁₋₆; -(alquilo C₀₋₄)-cicloalquilo C₃₋₆; (alquilo C₀₋₄)-arilo C₆₋₁₄ opcionalmente sustituido por uno o más grupos seleccionados a partir de: alquilo C₁₋₆, alcoxilo C₁₋₆ y halógeno; y (alquilo C₀₋₄)-heterociclilo de 3- a 14- miembros opcionalmente sustituidos por uno o más grupos seleccionados a partir de: halógeno, oxo, alquilo C₁₋₆ y C(O)alquilo C₁₋₆; ó R⁹ y R¹¹ junto con el átomo de nitrógeno al cual están fijados forman un heterociclilo de 5 a 10 miembros, dicho heterociclilo incluye 0 a 3 heteroátomos adicionales seleccionados a partir de N, O y S, el heterociclilo siendo opcionalmente sustituido por uno o más sustituyentes seleccionados a partir de: OH; halógeno; fenilo, heterociclilo de 5 a 10 miembros; alquilo C₁₋₆; haloalquilo C₁₋₆; alcoxilo C₁₋₆ opcionalmente sustituido por uno o más OH ó alcoxilo C₁₋₄; y C(O)O-alquilo C₁₋₆; en donde los grupos sustituyentes fenilo y heterociclilo son por sí mismos opcionalmente sustituidos por alquilo C₁₋₆, haloalquilo C₁₋₆ ó alcoxilo C₁₋₆; R¹⁵ se selecciona a partir de H; alquilo C₁₋₈; haloalquilo C₁₋₈; cicloalquilo C₃₋₁₀; -(alquilo C₁₋₄)-cicloalquilo C₃₋₈; -(alquilo C₀₋₄)-arilo C₆₋₁₄ y -(alquilo C₀₋₄)-grupo heterociclilo de 3 a 14 miembros; en donde el cicloalquilo C₃₋₁₀, -(alquilo C₁₋₄)-cicloalquilo C₃₋₈, -(alquilo C₀₋₄)-arilo C₆₋₁₄ y -(alquilo C₀₋₄)-grupo heterociclilo de 3 a 14 miembros son cada uno opcionalmente sustituidos por uno o más sustituyentes de Z; R¹⁸ᵃ es independientemente H ó alquilo C₁₋₆; R¹⁹ᵃ y R²¹ᵃ son cada uno independientemente H; alquilo C₁₋₆ opcionalmente sustituido por uno o más alcoxilo C₁₋₄, -NR²²R²³, u OH; haloalquilo C₁₋₆; -(alquilo C₀₋₁)-cicloalquilo C₃₋₆; -(alquilo C₀₋₄)-arilo C₆₋₁₄ opcionalmente sustituido por uno o más grupos seleccionados a partir de: alquilo C₁₋₆, alcoxilo C₁₋₆ y halógeno; ó -(alquilo C₀₋₄)-heterociclilo de 3- a 14- miembros opcionalmente sustituidos por uno o más grupos seleccionados a partir de: halógeno, oxo, alquilo C₁₋₆ y C(O)alquilo C₁₋₆; ó R¹⁹ᵃ y R²¹ᵃ junto con el átomo de nitrógeno al cual están fijados forman un heterociclilo de 5 a 10 miembros, dicho heterociclilo incluye 0 a 3 heteroátomos adicionales seleccionados a partir de N, O y S, el heterociclilo siendo opcionalmente sustituido por uno o más sustituyentes seleccionados a partir de: OH; halógeno; fenilo; heterociclilo de 5 a 10 miembros; alquilo C₁₋₆; haloalquilo C₁₋₆; alcoxilo C₁₋₆ opcionalmente sustituido por uno o más OH ó alcoxilo C₁₋₄; y C(O)O-alquilo C₁₋₆; en donde los grupos sustituyentes fenilo y heterociclilo son por sí mismos opcionalmente sustituidos por alquilo C₁₋₆, haloalquilo C₁₋₆ ó alcoxilo C₁₋₆; R¹⁸ es independientemente H ó alquilo C₁₋₆; R¹⁹ y R²¹ son cada uno independie
ARP120103226A 2011-09-01 2012-08-31 Derivados de heterociclos biciclicos para el tratamiento de la hipertension arterial pulmonar AR087755A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530049P 2011-09-01 2011-09-01
US201261680119P 2012-08-06 2012-08-06

Publications (1)

Publication Number Publication Date
AR087755A1 true AR087755A1 (es) 2014-04-16

Family

ID=47018333

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103226A AR087755A1 (es) 2011-09-01 2012-08-31 Derivados de heterociclos biciclicos para el tratamiento de la hipertension arterial pulmonar

Country Status (28)

Country Link
US (2) US8883819B2 (es)
EP (1) EP2751108B1 (es)
JP (1) JP5815870B2 (es)
KR (1) KR101687082B1 (es)
CN (2) CN105001218B (es)
AP (1) AP3818A (es)
AR (1) AR087755A1 (es)
AU (1) AU2012303674B2 (es)
BR (1) BR112014004631B1 (es)
CA (1) CA2845753C (es)
CL (1) CL2014000459A1 (es)
CO (1) CO6900139A2 (es)
CR (1) CR20140099A (es)
EA (1) EA024068B1 (es)
ES (1) ES2585048T3 (es)
IL (1) IL231228A0 (es)
MA (1) MA35364B1 (es)
MX (1) MX360316B (es)
PE (1) PE20141674A1 (es)
PH (1) PH12014500407A1 (es)
PL (1) PL2751108T3 (es)
PT (1) PT2751108T (es)
SG (1) SG11201400253YA (es)
TN (1) TN2014000067A1 (es)
TW (1) TW201313718A (es)
UY (1) UY34305A (es)
WO (1) WO2013030802A1 (es)
ZA (1) ZA201401294B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2685903B2 (ja) 1989-07-05 1997-12-08 アルプス電気株式会社 磁気ヘッド支持装置
UY34305A (es) * 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
WO2015089137A1 (en) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines as tryptophan hydroxylase inhibitors
CN105524058B (zh) * 2014-10-21 2018-03-27 广州艾格生物科技有限公司 吡唑并[1,5‑a]吡啶类化合物及其应用
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
GB201801355D0 (en) * 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
EP3880680A1 (en) 2018-11-14 2021-09-22 Altavant Sciences GmbH A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin
MX2022007044A (es) * 2019-12-13 2022-06-24 Nippon Shinyaku Co Ltd Compuesto y composicion como inhibidor de cinasa del receptor de los factores de crecimiento derivados de las plaquetas (pdgf).
US20220031633A1 (en) * 2020-07-28 2022-02-03 Yale University Poly(amine-co-ester) polymeric particles for selective pulmonary delivery
TW202241914A (zh) 2020-12-23 2022-11-01 瑞士商艾克泰聯製藥有限公司 吡唑并噻唑羧醯胺及其作為ｐｄｇｆｒ抑制劑之用途
TW202313053A (zh) 2021-07-30 2023-04-01 瑞士商艾克泰聯製藥有限公司 吡唑并嘧啶及其作為ｐｄｇｆｒ抑制劑之用途
CN113912530A (zh) * 2021-11-10 2022-01-11 山东汇海医药化工有限公司 一种4-aa中间体废液的处理方法
WO2023247590A1 (en) 2022-06-22 2023-12-28 Actelion Pharmaceuticals Ltd Triazolopyridine and benzoisoxazole carboxamides and their uses as pdgfr inhibitors
WO2023247595A1 (en) 2022-06-22 2023-12-28 Actelion Pharmaceuticals Ltd Pyrazolopyrazine carboxamides and their uses as pdgfr inhibitors
WO2023247593A1 (en) 2022-06-22 2023-12-28 Actelion Pharmaceuticals Ltd Pyrrolopyridine carboxamides and their uses as pdgfr inhibitors
WO2023247596A1 (en) 2022-06-22 2023-12-28 Actelion Pharmaceuticals Ltd Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
WO2024104968A1 (en) 2022-11-14 2024-05-23 Actelion Pharmaceuticals Ltd Pyrazolopyrrolopyridazines and their uses as pdgfr inhibitors
JP2025540958A (ja) 2022-11-30 2025-12-17 ブループリント メディシンズ コーポレイション 蕁麻疹の治療のための野生型ｃ－ｋｉｔキナーゼ阻害剤としてのＮ－フェニル－ピラゾロ［１，５－Ａ］ピリジン－３－カルボキサミド誘導体

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
ZA81219B (en) 1980-01-23 1982-01-27 Schering Corp Imidazo (1,2-a) pyridines ,process for their preparation and pharmaceutical compositions containing them
JPS6235216A (ja) 1985-08-09 1987-02-16 Noritoshi Nakabachi 不均質物質層の層厚非破壊測定方法および装置
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
WO1993018007A1 (fr) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Nouveau derive de carbostyrile
SK279958B6 (sk) 1992-04-02 1999-06-11 Smithkline Beecham Corporation Zlúčeniny s protialergickým a protizápalovým účink
JP3192424B2 (ja) 1992-04-02 2001-07-30 スミスクライン・ビーチャム・コーポレイション アレルギーまたは炎症疾患の治療用化合物
WO1993019751A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
DE59605366D1 (de) 1995-12-07 2000-07-06 Jago Pharma Ag Muttenz Inhalator zur mehrfachen dosisweisen abgabe eines pharmakologischen trockenpulvers
ES2172763T3 (es) 1996-02-21 2002-10-01 Schering Corp Inhalador de medicamento en polvo.
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
ATE260103T1 (de) 1997-12-19 2004-03-15 Schering Ag Ortho-anthranilamide derivate als antikoagulantien
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
BR9815931A (pt) 1998-06-30 2001-02-20 Dow Chemical Co Polióis poliméricos, um processo para sua produção, e espuma de poliuretanoobtida
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
TR200100300T2 (tr) 1998-08-04 2001-07-23 Astrazeneca Ab Sitokinlerin üretiminde engelleyici olarak kullanışlı amid türevleri
AU761291B2 (en) 1999-03-17 2003-05-29 Astrazeneca Ab Amide derivatives
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
CA2371583C (en) 1999-05-04 2005-09-13 Schering Corporation Piperazine derivatives useful as ccr5 antagonists
PT1175402E (pt) 1999-05-04 2005-11-30 Schering Corp Derivados da piperidina uteis como antagonistas ccr5
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
HU229439B1 (hu) 1999-08-21 2013-12-30 Takeda Gmbh Roflumilast és salmeterol szinergetikus kombinációja
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
BR0014076A (pt) 1999-09-17 2002-10-15 Millennium Pharm Inc Benzamidas e inibidores correlatos do fator xa
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
PL362868A1 (en) 2000-04-27 2004-11-02 Boehringer Ingelheim Pharma Gmbh & Co.Kg Novel, slow-acting betamimetics, a method for their production and their use as medicaments
IL153707A0 (en) 2000-06-27 2003-07-06 S A L V A T Lab Sa Carbamates derived from arylalkylamines
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
CZ304043B6 (cs) 2000-08-05 2013-09-04 Glaxo Group Limited Estery steroidních thiokyselin
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
AU2002228015B2 (en) 2000-12-22 2007-08-23 Almirall, S.A. Quinuclidine carbamate derivatives and their use as M3 antagonists
CA2433128C (en) 2000-12-28 2010-05-25 Almirall Prodesfarma Ag Novel quinuclidine derivatives and medicinal compositions containing the same
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
SE0100567D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
ATE365720T1 (de) 2001-03-08 2007-07-15 Glaxo Group Ltd Agonisten von beta-adrenorezeptoren
WO2002076933A1 (en) 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
US7291608B2 (en) 2001-04-30 2007-11-06 Glaxo Group Limited Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α
ES2307751T3 (es) 2001-06-12 2008-12-01 Glaxo Group Limited Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano.
DK2327765T3 (en) 2001-06-21 2015-07-13 Basf Enzymes Llc nitrilases
BRPI0212455B8 (pt) 2001-09-14 2021-05-25 Glaxo Group Ltd composto derivado de fenetanolamina para o tratamento de doenças respiratórias, formulação farmacêutica, combinação, e, uso do mesmo
HUP0401849A3 (en) 2001-10-17 2007-05-02 Ucb Sa Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
MY130622A (en) 2001-11-05 2007-07-31 Novartis Ag Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
WO2003048181A1 (en) 2001-12-01 2003-06-12 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
EA006505B1 (ru) 2001-12-20 2005-12-29 Лабораториос С.А.Л.В.А.Т.,С.А. Производные карбамата 1-алкил-1-азониабицикло[2.2.2]октана и их применение в качестве антагонистов мускаринового рецептора
WO2003072592A1 (en) 2002-01-15 2003-09-04 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
AU2003201693A1 (en) 2002-01-21 2003-09-02 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
EP1485384A1 (en) 2002-03-13 2004-12-15 Pharmacia & Upjohn Company LLC Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators
EA008830B1 (ru) 2002-03-26 2007-08-31 Бёрингер Ингельхайм Фармасьютиклз, Инк. Миметики глюкокортикоидов, способы их получения, фармацевтические композиции и их применение
WO2003082787A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
ATE496620T1 (de) 2002-04-11 2011-02-15 Merck Sharp & Dohme 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
EP1497261B1 (en) 2002-04-25 2007-12-19 Glaxo Group Limited Phenethanolamine derivatives
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP2005527618A (ja) 2002-05-28 2005-09-15 セラヴァンス インコーポレーテッド アルコキシアリールβ２アドレナリン作動性レセプターアゴニスト
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
ES2201907B1 (es) 2002-05-29 2005-06-01 Almirall Prodesfarma, S.A. Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos.
DE10224888A1 (de) 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10225574A1 (de) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
DE10227269A1 (de) 2002-06-19 2004-01-08 Merck Patent Gmbh Thiazolderivate
WO2004000814A1 (en) 2002-06-25 2003-12-31 Merck Frosst Canada & Co. 8-(biaryl) quinoline pde4 inhibitors
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
US20060004056A1 (en) 2002-07-02 2006-01-05 Bernard Cote Di-aryl-substituted-ethan pyridone pde4 inhibitors
DK1521733T3 (da) 2002-07-08 2014-10-13 Pfizer Prod Inc Modulatorer af glucocorticoid receptoren
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AR040962A1 (es) 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
JP2005538138A (ja) 2002-08-10 2005-12-15 アルタナ　ファルマ　アクチエンゲゼルシャフト Ｐｄｅ４インヒビターとしてのピリダジノン誘導体
AU2003260371A1 (en) 2002-08-10 2004-03-11 Altana Pharma Ag Piperidine-n-oxide-derivatives
AU2003255376A1 (en) 2002-08-10 2004-03-11 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
WO2004018457A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors
WO2004018431A2 (en) 2002-08-17 2004-03-04 Altana Pharma Ag Novel phenanthridines
JP2005537313A (ja) 2002-08-17 2005-12-08 アルタナ　ファルマ　アクチエンゲゼルシャフト 新規のベンゾナフチリジン
CA2496175A1 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
SE0202483D0 (sv) 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
DE60231341D1 (de) 2002-08-23 2009-04-09 Ranbaxy Lab Ltd Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
NZ538932A (en) 2002-08-29 2007-04-27 Boehringer Ingelheim Pharma 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative disease
ES2281658T3 (es) 2002-08-29 2007-10-01 Nycomed Gmbh 3-hidroxi-6-fenilfenantridinas como inhibidores de pde-4.
WO2004019944A1 (en) 2002-08-29 2004-03-11 Altana Pharma Ag 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
CA2497903A1 (en) 2002-09-18 2004-04-01 Ono Pharmaceutical Co., Ltd. Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
JP2006096662A (ja) 2002-09-18 2006-04-13 Sumitomo Pharmaceut Co Ltd 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤
AU2003270846B2 (en) 2002-09-19 2006-11-23 Merck Sharp & Dohme Corp. Pyrazolopyridines as cyclin dependent kinase inhibitors
JP4845379B2 (ja) 2002-09-19 2011-12-28 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのイミダゾピリジン
JP2004107299A (ja) 2002-09-20 2004-04-08 Japan Energy Corp 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤
CA2499150A1 (en) 2002-09-20 2004-04-01 Merck & Co., Inc. Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
DE10246374A1 (de) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
BR0315234A (pt) 2002-10-11 2005-08-23 Pfizer Derivados de indol como agonistas beta-2
EP1440966A1 (en) 2003-01-10 2004-07-28 Pfizer Limited Indole derivatives useful for the treatment of diseases
WO2004037807A2 (en) 2002-10-22 2004-05-06 Glaxo Group Limited Medicinal arylethanolamine compounds
DE60317918T2 (de) 2002-10-23 2009-01-29 Glenmark Pharmaceuticals Ltd. Tricyclische verbindungen zur behandlung von entzündlichen und allergischen erkrankungen verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
NZ539676A (en) 2002-10-28 2006-10-27 Glaxo Group Ltd Phenethanolamine derivative for the treatment of respiratory diseases
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
DE10253426B4 (de) 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE10253220A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
DE10261874A1 (de) 2002-12-20 2004-07-08 Schering Ag Nichtsteroidale Entzündungshemmer
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
WO2004066920A2 (en) 2003-01-21 2004-08-12 Merck & Co. Inc. 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
DE502004009440D1 (de) 2003-04-03 2009-06-10 Merck Patent Gmbh Pyrrolidin-1,2-dicarbonsäure-1-(phenylamid)-2-(4-(3-oxo-morpholin-4-yl)-phenylamid) derivate und verwandte verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen
EP1479680A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Azaindole derivatives as Factor Xa inhibitors
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
AU2004245174A1 (en) 2003-06-10 2004-12-16 Ace Biosciences A/S Extracellular Aspergillus polypeptides
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
GB2407042B (en) 2003-10-17 2007-10-24 Vectura Ltd Inhaler
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US20050171172A1 (en) 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as PDGFR modulators
GEP20084572B (en) 2003-12-23 2008-12-25 Pfizer Novel quinoline derivatives
WO2005085227A1 (en) 2004-03-02 2005-09-15 Smithkline Beecham Corporation Inhibitors of akt activity
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
DE102004045796A1 (de) 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
CA2589773A1 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Pyridine carboxamide derivatives for use as anticancer agents
TW200635899A (en) 2004-12-22 2006-10-16 Astrazeneca Ab Chemical compounds
US20090105250A1 (en) 2005-01-26 2009-04-23 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2006225355B2 (en) 2005-03-21 2010-12-09 Helsinn Healthcare Sa Imidazo(1,2-a)pyridine derivatives: preparation and pharmaceutical applications
GB0507575D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
EP1919910B1 (en) * 2005-07-29 2011-02-23 F. Hoffmann-La Roche AG Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
CA2621983A1 (en) 2005-09-09 2007-03-22 Schering Corporation Azafused cyclin dependent kinase inhibitors
WO2007065664A2 (en) 2005-12-08 2007-06-14 Novartis Ag Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors
CA2637392A1 (en) * 2006-01-23 2007-07-26 Crystalgenomics, Inc. Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
GB0604937D0 (en) 2006-03-10 2006-04-19 Novartis Ag Organic compounds
WO2007113226A1 (en) 2006-03-31 2007-10-11 Novartis Ag Organic compounds
US20080015193A1 (en) 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
CN101511828A (zh) * 2006-09-06 2009-08-19 霍夫曼-拉罗奇有限公司 作为蛋白激酶抑制剂的杂芳基衍生物
RU2009120882A (ru) 2006-11-03 2010-12-10 Айрм Ллк (Bm) Соединения и композиции, как ингибиторы протеинкиназы
MX2009005144A (es) 2006-11-22 2009-05-27 Incyte Corp Imidazotriazinas e imidazopirimidinas como inhibidores de cinasa.
US8513276B2 (en) 2006-12-22 2013-08-20 Astex Therapeutics Limited Imidazo[1,2-a]pyridine compounds for use in treating cancer
EP2118069B1 (en) 2007-01-09 2014-01-01 Amgen Inc. Bis-aryl amide derivatives useful for the treatment of cancer
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
CA2691987C (en) 2007-06-12 2016-08-16 Achaogen, Inc. Antibacterial agents
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US8217064B2 (en) 2007-12-20 2012-07-10 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
US20100324086A1 (en) 2008-02-19 2010-12-23 Novasaid Ab Compounds and methods
BRPI0912668A2 (pt) 2008-05-13 2016-01-26 Irm Llc composto e composições como inibidores de quinase
US8455477B2 (en) 2008-08-05 2013-06-04 Merck Sharp & Dohme Corp. Therapeutic compounds
EP2210891A1 (en) 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
WO2010088000A2 (en) 2009-02-02 2010-08-05 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
CN102573846B (zh) 2009-08-17 2015-10-07 因特利凯公司 杂环化合物及其用途
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
US8501982B2 (en) 2010-06-09 2013-08-06 Receptos, Inc. GLP-1 receptor stabilizers and modulators
KR101491938B1 (ko) 2010-07-14 2015-02-10 노파르티스 아게 Ｉｐ 수용체 효능제 헤테로시클릭 화합물
JP2013538798A (ja) * 2010-08-03 2013-10-17 グラフィニティ ファーマシューティカルズ ゲーエムベーハー アフィニティクロマトグラフィーによる抗体およびＦｃ融合タンパク質精製のためのリガンド
ES2573148T3 (es) 2010-08-25 2016-06-06 Neopharm Co., Ltd. Compuestos y composición de 1H-benzo[d]imidazol-5-ilo para el tratamiento de enfermedades inflamatorias
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
UY34305A (es) * 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar

Also Published As

Publication number Publication date
UY34305A (es) 2013-04-30
JP5815870B2 (ja) 2015-11-17
CN104024252B (zh) 2015-08-26
CO6900139A2 (es) 2014-03-20
CN105001218A (zh) 2015-10-28
EA024068B1 (ru) 2016-08-31
US20150025059A1 (en) 2015-01-22
US9751876B2 (en) 2017-09-05
MA35364B1 (fr) 2014-08-01
EP2751108B1 (en) 2016-04-27
EA201490543A1 (ru) 2014-07-30
NZ621436A (en) 2015-10-30
PT2751108T (pt) 2016-08-04
ES2585048T3 (es) 2016-10-03
AP2014007539A0 (en) 2014-03-31
CL2014000459A1 (es) 2014-09-05
PH12014500407A1 (en) 2017-04-07
BR112014004631A2 (pt) 2017-03-14
PL2751108T3 (pl) 2016-11-30
HK1196126A1 (zh) 2015-03-20
TW201313718A (zh) 2013-04-01
CA2845753A1 (en) 2013-03-07
US8883819B2 (en) 2014-11-11
KR20140059272A (ko) 2014-05-15
SG11201400253YA (en) 2014-03-28
TN2014000067A1 (en) 2015-07-01
ZA201401294B (en) 2015-06-24
CA2845753C (en) 2021-04-20
CN105001218B (zh) 2017-04-12
IL231228A0 (en) 2014-04-30
AU2012303674A1 (en) 2014-03-13
CR20140099A (es) 2014-06-25
CN104024252A (zh) 2014-09-03
BR112014004631B1 (pt) 2020-02-11
JP2014527544A (ja) 2014-10-16
PE20141674A1 (es) 2014-11-14
EP2751108A1 (en) 2014-07-09
US20130237519A1 (en) 2013-09-12
AU2012303674B2 (en) 2015-11-26
KR101687082B1 (ko) 2016-12-15
WO2013030802A1 (en) 2013-03-07
AP3818A (en) 2016-09-30
MX2014002499A (es) 2014-05-30
MX360316B (es) 2018-10-29

Similar Documents

Publication Publication Date Title
AR087755A1 (es) Derivados de heterociclos biciclicos para el tratamiento de la hipertension arterial pulmonar
AR089698A1 (es) Compuestos heterociclicos antagonistas del receptor ip
AR098853A1 (es) Pirazoles sustituidos y usos de los mismos
RU2016115082A (ru) Замещенные аминопиримидиновые соединения и способы их использования
AR104884A1 (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR091368A1 (es) Compuestos y composiciones para modular la actividad de egfr
NO20091012L (no) Kinazolinon- og isokinolinonacetamid derivater
AR093308A1 (es) Derivados triciclicos fusionados de tiofeno como inhibidores de jak
AR094557A1 (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn
AR089699A1 (es) Imidazoles y pirazoles fusionados sustituidos y sus usos
AR103064A1 (es) Compuestos moduladores de fxr (nr1h4)
AR097571A1 (es) Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR078536A1 (es) Derivados de pirazol como ligandos del receptor de estrogeno
AR088014A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de la fosfodiesterasa
AR085637A1 (es) Derivados de pirido[2,3-b]pirazina
ES2626801T3 (es) Compuestos de triazolopiridina como inhibidores de pde10a
AR091261A1 (es) Derivados de alcoholes 1-fenil-2-piridinilalquilicos como inhibidores de la fosfodiesterasa
AR098104A1 (es) Composiciones pesticidas y métodos relacionados
AR106873A1 (es) Compuestos de piridina como fungicidas
AR088320A1 (es) Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt
AR098101A1 (es) Composiciones plaguicidas y métodos relacionados
AR095267A1 (es) Compuestos inhibidores de la fosfodiesterasa del tipo 10a
AR093035A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
AR119376A1 (es) Compuestos heterocíclicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure